Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide.

Por Toffoli, G., Sorio, R., Gigante, M., Corona, G., Galligioni, E., Boiocchi, M.
Publicado em 1997

2-weekly docetaxel: issues for clinical practice

Por Massari, F, Maines, F, Bria, E, Galligioni, E, Caffo, O, Tortora, G
Publicado no Cancer Biol Ther (2014)

Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer

Por Cappuzzo, F, Mazzoni, F, Gennari, A, Donati, S, Salvadori, B, Orlandini, C, Cetto, G L, Molino, A, Galligioni, E, Mansutti, M, Tumolo, S, Lucentini, A, Valduga, F, Bartolini, S, Crinò, L, Conte, P F
Publicado em 2004

Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG).

Por Bernhard, J., Hürny, C., Coates, A. S., Peterson, H. F., Castiglione-Gertsch, M., Gelber, R. D., Galligioni, E., Marini, G., Thürlimann, B., Forbes, J. F., Goldhirsch, A., Senn, H. J., Rudenstam, C. M.
Publicado em 1998